Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults – Part 1: Crohn’s disease
Frontline Gastroenterology review of BSG… · 2025 · United Kingdom
Source and licence
- Authors
- Thomas D Butler, Jonathan P Segal
- Title
- Guideline review: 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults – Part 1: Crohn’s disease
- Journal
- Frontline gastroenterology, 2025
- Licence
- CC BY 4.0
- Changes
- Verbatim excerpts; formatting adapted
Full text retrieved 2026-10-27 from Europe PMC · PMC7619136
Licence statement of the original publication
This work is licensed under a CC BY 4.0 International license.
This page reproduces excerpts of the original publication; the original is authoritative. It has not been reviewed by a physician, does not state a recommendation of Medelix and does not replace medical advice. The guideline may have been updated since.
Open the original publication →Full text on Europe PMC
Recommendations
We found no explicitly labelled recommendations in this publication; its recommendations are in the running text of the original.
Abstract
This guideline review summarises the key recommendations for the diagnosis and management of Crohn’s disease from the updated 2025 British Society of Gastroenterology guidelines on inflammatory bowel disease in adults.
Contents of the original publication
The section headings of the original.
- Introduction
- Methodology
- Diagnosis and monitoring of Crohn’s disease
- Management of Crohn’s disease
- A ‘top down’ approach to treatment of moderate to severe Crohn’s disease
- Immunomodulator monotherapy
- Advanced therapy
- Therapeutic drug monitoring
- Vedolizumab is not suggested for induction and maintenance of remission in patients with moderate to severe Crohn’s disease
- Surgery in Crohn’s disease
- Maintenance of remission post-ileocaecal resection
- Future directions
- Conclusions
A question about this guideline?
Medelix answers clinical questions from guidelines and studies – every statement with its source.
Are you the rights holder and object to this reproduction? Write to contact@medelix.ai and we will take the page down promptly. Imprint